{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:10:03Z","timestamp":1759039803064,"version":"3.44.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.psychres.2020.112990","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T20:01:14Z","timestamp":1586548874000},"page":"112990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evidence of new-onset depression among persons with migraine after discontinuing antidepressants"],"prefix":"10.1016","volume":"288","author":[{"given":"Brent M.","family":"Kious","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda V.","family":"Bakian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Selected prescription drug classes used in the past 30 days, by sex and age: United States, 2009\u20132012","key":"10.1016\/j.psychres.2020.112990_bib0001"},{"year":"2017","series-title":"Antidepressant use among persons aged 12 and over: United States, 2011\u20132014","author":"Pratt","key":"10.1016\/j.psychres.2020.112990_bib0002"},{"key":"10.1016\/j.psychres.2020.112990_bib0003","doi-asserted-by":"crossref","first-page":"e6989","DOI":"10.1097\/MD.0000000000006989","article-title":"Tricyclic antidepressants for preventing migraine in adults","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.psychres.2020.112990_bib0004","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults","volume":"4","author":"Banzi","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2018","key":"10.1016\/j.psychres.2020.112990_bib0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/head.13375","article-title":"Pharmacologic prevention of migraine: a narrative review of the state of the art","volume":"58","author":"Loder","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.psychres.2020.112990_bib0006","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1755-5949.2010.00170.x","article-title":"The use of antidepressants for headache prophylaxis","volume":"17","author":"Smitherman","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.psychres.2020.112990_bib0007","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/head.12205","article-title":"Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study","volume":"53","author":"Young","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.psychres.2020.112990_bib0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"Ozyalcin","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.psychres.2020.112990_bib0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fneur.2017.00524","article-title":"The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.psychres.2020.112990_bib0010","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","article-title":"Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study","volume":"107","author":"Bulut","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.psychres.2020.112990_bib0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/WNF.0b013e3181a8c84f","article-title":"Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders","volume":"32","author":"Tarlaci","year":"2009","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.psychres.2020.112990_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011603","article-title":"Amitriptyline for neuropathic pain in adults","volume":"7","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst. Rev"},{"key":"10.1016\/j.psychres.2020.112990_bib0014","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.mayocp.2015.01.018","article-title":"Neuropathic pain: principles of diagnosis and treatment","volume":"90","author":"Gilron","year":"2015","journal-title":", Mayo Clin. Proc"},{"key":"10.1016\/j.psychres.2020.112990_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.psychres.2020.112990_bib0016","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pop.2018.02.008","article-title":"Fibromyalgia in primary care","volume":"45","author":"Higgs","year":"2018","journal-title":"Prim. Care"},{"key":"10.1016\/j.psychres.2020.112990_bib0017","article-title":"Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia","volume":"2","author":"Welsch","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2020.112990_bib0018","series-title":"Vital signs: trends in state suicide rates \u2014 United States, 1999\u20132016, and circumstances contributing to suicide \u2014 27 States, 2015","first-page":"617","author":"Stone","year":"2018"},{"key":"10.1016\/j.psychres.2020.112990_bib0019","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/DBP.0000000000000571","article-title":"Epidemiology and impact of health care provider\u2013diagnosed anxiety and depression among US children, J","volume":"39","author":"Bitsko","year":"2018","journal-title":"Dev. Behav. Pediatr."},{"year":"2010","series-title":"Anatomy of an epidemic: magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America","author":"Whitaker","key":"10.1016\/j.psychres.2020.112990_bib0020"},{"key":"10.1016\/j.psychres.2020.112990_bib0021","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.mehy.2011.01.020","article-title":"Tardive dysphoria: the role of long term antidepressant use in-inducing chronic depression","volume":"76","author":"El-Mallakh","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.psychres.2020.112990_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0790966700011976","article-title":"Tardive dysphoria: antidepressant-induced chronic depression","volume":"28","author":"El-Mallakh","year":"2011","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.psychres.2020.112990_bib0023","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000362803","article-title":"Rational use of antidepressant drugs","volume":"83","author":"Fava","year":"2014","journal-title":"Psychother. Psychosom"},{"key":"10.1016\/j.psychres.2020.112990_bib0024","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.phrs.2018.10.025","article-title":"The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications","volume":"139","author":"Fornaro","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.psychres.2020.112990_bib0025","first-page":"129","article-title":"Tachyphylaxis\/tolerance to antidepressive medications: a review","volume":"48","author":"Katz","year":"2011","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0026","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1440-1819.2011.02231.x","article-title":"Tachyphylaxis\/tolerance to antidepressants in treatment of dysthymia: results of a retrospective naturalistic chart review study","volume":"65","author":"Katz","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2020.112990_bib0027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0306-9877(84)90018-5","article-title":"Antidepressant tachyphylaxis","volume":"15","author":"Lieb","year":"1984","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.psychres.2020.112990_bib0028","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4088\/JCP.v68n0814","article-title":"How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low","volume":"68","author":"Zimmerman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000226611","article-title":"Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder","volume":"59","author":"Amsterdam","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2020.112990_bib0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0010-440X(89)90048-5","article-title":"Treatment-emergent depression with antidepressants in panic disorder","volume":"30","author":"Aronson","year":"1989","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0031","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0447.1993.tb03448.x","article-title":"Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors","volume":"88","author":"Fux","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2020.112990_bib0032","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S1461145706007462","article-title":"Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia","volume":"10","author":"Fava","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0033","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators?","author":"Vinkers","year":"2012","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0034","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited\u2013will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2020.112990_bib0035","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","author":"O'Brien","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10550887.2014.882725","article-title":"An update on zolpidem abuse and dependence","volume":"33","author":"Victorri-Vigneau","year":"2014","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.psychres.2020.112990_bib0037","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0301-0082(96)00011-1","article-title":"The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs","volume":"49","author":"Hutchinson","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.psychres.2020.112990_bib0038","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.5664\/jcsm.7240","article-title":"Severe chronic abuse of zolpidem in refractory insomnia, J","volume":"14","author":"Chiaro","year":"2018","journal-title":"Clin. Sleep Med."},{"key":"10.1016\/j.psychres.2020.112990_bib0039","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management","volume":"7","author":"Ward","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.psychres.2020.112990_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","article-title":"Tardive dyskinesia: epidemiology","volume":"389","author":"D'Abreu","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0041","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","article-title":"Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment","volume":"78","author":"Correll","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0042","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2018.02.004","article-title":"Future directions in tardive dyskinesia research","volume":"389","author":"Meyer","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1092852916000730","article-title":"Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia","volume":"21","author":"Meyer","year":"2016","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psychres.2020.112990_bib0044","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.25909","article-title":"Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model","volume":"29","author":"Mahmoudi","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.psychres.2020.112990_bib0045","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2020.112990_bib0046","series-title":"Neurotoxin Modeling of Brain Disorders\u2014Life-long Outcomes in Behavioral Teratology","first-page":"353","article-title":"Lifelong rodent model of tardive dyskinesia-persistence after antipsychotic drug withdrawal","author":"Kostrzewa","year":"2015"},{"key":"10.1016\/j.psychres.2020.112990_bib0047","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0269881117728428","article-title":"Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice","volume":"31","author":"Nakata","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0048","doi-asserted-by":"crossref","first-page":"30144","DOI":"10.3390\/ijms161226228","article-title":"Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia","volume":"16","author":"Oda","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0049","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2020.112990_bib0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1570159X14666160606093602","article-title":"Antipsychotic-induced dopamine supersensitivity psychosis: a comprehensive review","volume":"15","author":"Yin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0051","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0269881109359097","article-title":"A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis","volume":"25","author":"Fallon","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0052","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1176\/ajp.150.4.566","article-title":"Further evidence that a placebo response to antidepressants can be identified","volume":"150","author":"Quitkin","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0053","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","article-title":"Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database","volume":"25","author":"Serna","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0054","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/03007995.2011.576663","article-title":"Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases","volume":"27","author":"Wang","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.psychres.2020.112990_bib0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jad.2010.03.001","article-title":"Risk factors of treatment resistance in major depression: association with bipolarity","volume":"126","author":"Dudek","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2020.112990_bib0056","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2004.01.015","article-title":"A closer look at treatment resistant depression: is it due to a bipolar diathesis?","volume":"84","author":"Sharma","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2020.112990_bib0057","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2008.07.011","article-title":"Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice","volume":"593","author":"Gunther","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0058","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1152\/jn.00109.2007","article-title":"Reduced 5-HT1A- and GABAB receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats","volume":"98","author":"Cornelisse","year":"2007","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.psychres.2020.112990_bib0059","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/mp.2008.35","article-title":"Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders","volume":"14","author":"Spindelegger","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuroscience.2017.05.021","article-title":"Chronic fluoxetine rescues changes in plasma membrane density of 5-HT1A autoreceptors and serotonin transporters in the olfactory bulbectomy rodent model of depression","volume":"356","author":"Riad","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.psychres.2020.112990_bib0061","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0028-3908(99)00088-X","article-title":"Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine","volume":"39","author":"Le Poul","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2020.112990_bib0062","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.bjp.0704555","article-title":"Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography","volume":"135","author":"Pejchal","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0063","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1523\/JNEUROSCI.0950-04.2004","article-title":"Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat","volume":"24","author":"Riad","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.psychres.2020.112990_bib0064","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1098\/rstb.2011.0361","article-title":"Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT","volume":"367","author":"Descarries","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"10.1016\/j.psychres.2020.112990_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2018.03.005","article-title":"Deep brain stimulation and fluoxetine exert different long-term changes in the serotonergic system","volume":"135","author":"Volle","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.psychres.2020.112990_bib0066","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/14767058.2017.1317342","article-title":"Perinatal SSRI exposure permanently alters cerebral serotonin receptor mRNA in mice but does not impact adult behaviors","volume":"31","author":"Meyer","year":"2018","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"10.1016\/j.psychres.2020.112990_bib0067","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/syn.20721","article-title":"Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats","volume":"64","author":"Kovacevic","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.psychres.2020.112990_bib0068","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1471-4159.2007.05201.x","article-title":"Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline","volume":"105","author":"Rossi","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psychres.2020.112990_bib0069","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0197-0186(00)00043-7","article-title":"Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study","volume":"38","author":"Hebert","year":"2001","journal-title":"Neurochem. Int"},{"key":"10.1016\/j.psychres.2020.112990_bib0070","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1523\/JNEUROSCI.19-23-10494.1999","article-title":"Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level","volume":"19","author":"Benmansour","year":"1999","journal-title":"J. Neurosci"},{"key":"10.1016\/j.psychres.2020.112990_bib0071","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(98)00997-5","article-title":"Chronic amitriptyline administration increases serotonin transporter binding sites in the hippocampus of aged rats","volume":"261","author":"Yau","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.psychres.2020.112990_bib0072","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biopsych.2006.02.029","article-title":"Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain","volume":"61","author":"Gould","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0073","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0006-3223(03)00676-0","article-title":"Regulation of the norepinephrine transporter by chronic administration of antidepressants","volume":"55","author":"Benmansour","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0074","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.npp.1300036","article-title":"Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration","volume":"28","author":"Kugaya","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2020.112990_bib0075","first-page":"1593","article-title":"The mechanisms of tolerance in antidepressant action, Progress in Neuro-Psychopharmacology and Biol","volume":"35","author":"Fava","year":"2011","journal-title":"Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0076","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/ajp.142.4.441","article-title":"Fibromyalgia and major affective disorder: a controlled phenomenology and family history study","volume":"142","author":"Hudson","year":"1985","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0077","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.genhosppsych.2009.07.002","article-title":"Axis I and Axis II psychiatric disorders in patients with fibromyalgia","volume":"32","author":"Uguz","year":"2010","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2020.112990_bib0078","first-page":"94","article-title":"Self-reported depression, familial history of depression and fibromyalgia (FM), and psychological distress in patients with FM, Z","volume":"57","author":"Offenbaecher","year":"1998","journal-title":"Rheumatol."},{"key":"10.1016\/j.psychres.2020.112990_bib0079","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4088\/JCP.v67n0807","article-title":"Comorbidity of fibromyalgia and psychiatric disorders","volume":"67","author":"Arnold","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0080","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/070674370505001305","article-title":"Comorbidity of major depression and migraine \u2014 a Canadian population-based study","volume":"50","author":"Molgat","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0081","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1468-2982.2003.00518.x","article-title":"Co-morbidity of migraine and major depression in the Turkish population","volume":"23","author":"Kececi","year":"2003","journal-title":"Cephalalgia"},{"key":"10.1016\/j.psychres.2020.112990_bib0082","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1468-2982.2008.01571.x","article-title":"Anticonvulsants in migraine prophylaxis: a Cochrane review","volume":"28","author":"Mulleners","year":"2008","journal-title":"Cephalalgia"},{"key":"10.1016\/j.psychres.2020.112990_bib0083","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12888-016-1172-3","article-title":"Psychiatric readmissions and their association with physical comorbidity: a systematic literature review","volume":"17","author":"Sprah","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0084","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J","volume":"40","author":"Charlson","year":"1987","journal-title":"Chronic Dis"},{"key":"10.1016\/j.psychres.2020.112990_bib0085","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index, J","volume":"47","author":"Charlson","year":"1994","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.psychres.2020.112990_bib0086","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.psychres.2020.112990_bib0087","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/da.22854","article-title":"Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders","volume":"36","author":"Jakubovski","year":"2019","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.psychres.2020.112990_bib0088","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","article-title":"Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review","volume":"19","author":"Strawn","year":"2018","journal-title":"Expert Opin. Pharmacother"},{"issue":"Suppl 7","key":"10.1016\/j.psychres.2020.112990_bib0089","first-page":"5","article-title":"Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition","volume":"58","author":"Schatzberg","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2020.112990_bib0091","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jad.2015.02.032","article-title":"A meta-analysis investigating the prevalence and moderators of migraines among people with bipolar disorder","volume":"178","author":"Fornaro","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2020.112990_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.comppsych.2014.09.020","article-title":"Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: a systematic review","volume":"56","author":"Fornaro","year":"2015","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.psychres.2020.112990_bib0093","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","article-title":"Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists","volume":"56","author":"Gray","year":"2001","journal-title":"Brain Res. Bull"},{"key":"10.1016\/j.psychres.2020.112990_bib0094","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2012.09.006","article-title":"Serotonin receptors involved in antidepressant effects","volume":"137","author":"Artigas","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2020.112990_bib0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.pra.0000450323.37038.a9","article-title":"Emerging mania following escitalopram withdrawal in a patient with unipolar depression managed with its reintroduction, J","volume":"20","author":"de Berardis","year":"2014","journal-title":"Psychiatr. Pract."},{"key":"10.1016\/j.psychres.2020.112990_bib0096","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.psychres.2020.112990_bib0097","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","article-title":"Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites","volume":"283","author":"Owens","year":"1997","journal-title":"J. Pharmacol. Exper. Ther."},{"key":"10.1016\/j.psychres.2020.112990_bib0098","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1527-3458.2002.tb00234.x","article-title":"Duloxetine pharmacology: profile of a dual monoamine modulator","volume":"8","author":"Karpa","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.psychres.2020.112990_bib0099","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2174\/1381612053764805","article-title":"The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression","volume":"11","author":"Bymaster","year":"2005","journal-title":"Curr. Pharm. Des."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120305072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120305072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:40:58Z","timestamp":1759038058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120305072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":99,"alternative-id":["S0165178120305072"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.112990","relation":{},"ISSN":["0165-1781"],"issn-type":[{"type":"print","value":"0165-1781"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence of new-onset depression among persons with migraine after discontinuing antidepressants","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.112990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112990"}}